• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·1177.HK
Share

Sino Biopharmaceutical Limited Stocks

HK$ 5.15Last Updated 20.11.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

HK$ 12.61B

HK$ 5.15
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 1177.HK is 8.01 and suggests 49.3% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

20.11.2026 13:46

Not Waiting for the Bottom: Burry Bought More of Tencent, BYD, and Adobe Shares as Their Prices Fell

20.11.2026 13:23

The short seller who highlighted Nvidia's problems has set his sights on a new target: Cerebras shares

20.11.2026 12:57

Stress Test: Which Nvidia Suppliers Will Be Hit Hardest After Huang's Departure?

20.11.2026 11:48

Anthropic's IPO Triggered a Sell-Off of Chipmakers' Stocks in Asia. What Should Investors Do?

20.11.2026 11:20

Top Stories This Morning: Anthropic's Debut, a Sale in Asia, Another IPO Cancellation, and Apple's AI Agent

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026